Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism

被引：3
作者：
Knepper, J. [1 ]
Ramacciotti, E. [1 ]
Wakefield, T. W. [1 ]
机构：
[1] Univ Michigan, Sch Med, Med Ctr, Conrad Jobst Vasc Res Labs,Sect Vasc Surg, Ann Arbor, MI 48109 USA
来源：
PHLEBOLOGY | 2011年 / 26卷 / 01期
关键词：
clinical trials; oral anticoagulants; venous thrombosis; drug design; FACTOR XA INHIBITOR; DEEP-VEIN THROMBOSIS; DABIGATRAN ETEXILATE; TOTAL HIP; KNEE ARTHROPLASTY; DOUBLE-BLIND; ORAL ANTICOAGULANTS; ENOXAPARIN; RIVAROXABAN; THROMBOPROPHYLAXIS;
D O I：
10.1258/phleb.2010.010023
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Traditional therapeutic oral anticoagulation strategies often require invasive dosing or monitoring. Vitamin K antagonists (VKAs) have a large number of interactions, delayed onset requires frequent dose monitoring, and they have a small margin between therapeutic dose and bleeding complications. Novel oral anticoagulants, such as dabigatran, rivaroxaban and apixaban, are being developed to prevent those VKAs drawbacks. Besides oral bioavailability, those compounds are designed to require minimal to no monitoring and have a favourable safety profile. This review reports efficacy and safety data of these compounds throughout clinical development, as well as new approaches for oral pharmacological management of venous thromboembolism.
引用
收藏
页码：3 / 7
页数：5
相关论文
共 25 条
  • [1] Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) - The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
    Agnelli, Giancarlo
    Gallus, Alexander
    Goldhaber, Samuel Z.
    Haas, Sylvia
    Huisman, Menno V.
    Hull, Russel D.
    Kakkar, Ajay K.
    Misselwitz, Frank
    Schellong, Sebastian
    [J]. CIRCULATION, 2007, 116 (02) : 180 - 187
  • [2] Borris LC, 2009, EXPERT OPIN PHARMACO, V10, P1083, DOI [10.1517/14656560902835513, 10.1517/14656560902835513 ]
  • [3] A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
    Buller, Harry R.
    Lensing, Anthonie W. A.
    Prins, Martin H.
    Agnelli, Giancarlo
    Cohen, Alexander
    Gallus, Alexander S.
    Misselwitz, Frank
    Raskob, Gary
    Schellong, Sebastian
    Segers, Annelise
    [J]. BLOOD, 2008, 112 (06) : 2242 - 2247
  • [4] Carr JA, 1999, J CARDIOVASC SURG, V40, P659
  • [5] Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial
    Eriksson, B. I.
    Dahl, O. E.
    Rosencher, N.
    Kurth, A. A.
    Van Dijk, N.
    Frostick, S. P.
    Kalebo, P.
    Christiansen, A. V.
    Hantel, S.
    Hettiarachchi, R.
    Schnee, J.
    Buller, H. R.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) : 2178 - 2185
  • [6] Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    Eriksson, Bengt I.
    Borris, Lars C.
    Friedman, Richard J.
    Haas, Sylvia
    Huisman, Menno V.
    Kakkar, Ajay K.
    Bandel, Tiemo J.
    Beckmann, Horst
    Muehlhofer, Eva
    Misselwitz, Frank
    Geerts, William
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) : 2765 - 2775
  • [7] Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
    Eriksson, Bengt I.
    Dahl, Ola E.
    Rosencher, Nadia
    Kurth, Andreas A.
    van Dijk, C. Niek
    Frostick, Simon P.
    Prins, Martin H.
    Hettiarachchi, Rohan
    Hantel, Stefan
    Schnee, Janet
    Bueller, Harry R.
    [J]. LANCET, 2007, 370 (9591) : 949 - 956
  • [8] A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial
    Eriksson, BI
    Dahl, OE
    Büller, HR
    Hettiarachchi, R
    Rosencher, N
    Bravo, ML
    Ahnfelt, L
    Piovella, F
    Stangier, J
    Kälebo, P
    Reilly, P
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) : 103 - 111
  • [9] Survival of heparins, oral anticoagulants, and aspirin after the year 2010
    Fareed, Jawed
    Hoppensteadt, Debra A.
    Fareed, Daniel
    Demir, Muzaffer
    Wahi, Rakesh
    Clarke, Melaine
    Adiguzel, Cafer
    Bick, Rodger
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 (01) : 58 - 73
  • [10] Dabigatran Etexilate Prevents Venous Thromboembolism After Total Knee Arthroplasty in Japanese Patients With a Safety Profile Comparable to Placebo
    Fuji, Takeshi
    Fuijita, Satoru
    Ujihira, Toru
    Sato, Toru
    [J]. JOURNAL OF ARTHROPLASTY, 2010, 25 (08) : 1267 - 1274
123